Targeting BRAF-mutant tumours with TGFBR1 inhibitors.
Division of Cancer Research, School of Medicine, University of Dundee, Dundee, UK.
Lindsay C
LC
Spender
Division of Cancer Research, School of Medicine, University of Dundee, Dundee, UK.
Gareth J
GJ
Inman
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D006801:Humans; D009154:Mutation; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D000077293:Receptor, Transforming Growth Factor-beta Type I; D018125:Receptors, Transforming Growth Factor beta / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D018125:Receptors, Transforming Growth Factor beta; C482119:BRAF protein, human; D017346:Protein Serine-Threonine Kinases; D048493:Proto-Oncogene Proteins B-raf; D000077293:Receptor, Transforming Growth Factor-beta Type I; C000625841:TGFBR1 protein, human
BRAF; TGFβ; melanoma; therapy